Carcinoid tumors are part of a heterogeneous group of gastrointestinal and pancreatic endocrine tumors that are characterized by their capacity to produce and secrete hormones, 5-hydroxytryptamine ...

Background. A 48-year-old man presented with diarrhea, flushing, abdominal pain and weight loss of 10 kg over a 6-month period. He subsequently developed dyspnea on exertion. Diagnosis. Carcinoid ...

Exelixis, Inc. (Nasdaq: EXEL) today announced that the U.S. Food and Drug Administration (FDA) has approved CABOMETYX® (cabozantinib) for the treatment of 1) adult and pediatric patients 12 years of ...

This significant leap is attributed to rising incidences of carcinoid tumors, especially in the lungs and gastrointestinal tract, matched with an increase in the development and utilization of ...

Neuroendocrine tumors that start in the pancreas tend to be more aggressive and have a poor prognosis.

our doctors are working to improve the understanding and treatment of neuroendocrine tumors of the gastrointestinal system. Neuroendocrine tumors act quite differently — and, as a result, are managed ...

Cabozantinib significantly improved progression free survival in patients with pNET and epNET compared with placebo.

The study was led by Jennifer Chan, MD, MPH, clinical director of the gastrointestinal cancer center and director of the program in carcinoid and neuroendocrine tumors at Dana-Farber Cancer Institute.

Key Challenges Despite the market's upward trajectory, there are notable challenges. Late-stage diagnoses due to early asymptomatic conditions, the high cost of treatments, and limited specialist ...